Literature DB >> 23999527

Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity.

C Hammer1, B Stepniak1, A Schneider2, S Papiol3, M Tantra3, M Begemann1, A-L Sirén4, L A Pardo5, S Sperling1, S Mohd Jofrry1, A Gurvich1, N Jensen1, K Ostmeier1, F Lühder6, C Probst7, H Martens8, M Gillis9, G Saher10, F Assogna11, G Spalletta11, W Stöcker7, T F Schulz9, K-A Nave12, H Ehrenreich3.   

Abstract

In 2007, a multifaceted syndrome, associated with anti-NMDA receptor autoantibodies (NMDAR-AB) of immunoglobulin-G isotype, has been described, which variably consists of psychosis, epilepsy, cognitive decline and extrapyramidal symptoms. Prevalence and significance of NMDAR-AB in complex neuropsychiatric disease versus health, however, have remained unclear. We tested sera of 2817 subjects (1325 healthy, 1081 schizophrenic, 263 Parkinson and 148 affective-disorder subjects) for presence of NMDAR-AB, conducted a genome-wide genetic association study, comparing AB carriers versus non-carriers, and assessed their influenza AB status. For mechanistic insight and documentation of AB functionality, in vivo experiments involving mice with deficient blood-brain barrier (ApoE(-/-)) and in vitro endocytosis assays in primary cortical neurons were performed. In 10.5% of subjects, NMDAR-AB (NR1 subunit) of any immunoglobulin isotype were detected, with no difference in seroprevalence, titer or in vitro functionality between patients and healthy controls. Administration of extracted human serum to mice influenced basal and MK-801-induced activity in the open field only in ApoE(-/-) mice injected with NMDAR-AB-positive serum but not in respective controls. Seropositive schizophrenic patients with a history of neurotrauma or birth complications, indicating an at least temporarily compromised blood-brain barrier, had more neurological abnormalities than seronegative patients with comparable history. A common genetic variant (rs524991, P=6.15E-08) as well as past influenza A (P=0.024) or B (P=0.006) infection were identified as predisposing factors for NMDAR-AB seropositivity. The >10% overall seroprevalence of NMDAR-AB of both healthy individuals and patients is unexpectedly high. Clinical significance, however, apparently depends on association with past or present perturbations of blood-brain barrier function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999527     DOI: 10.1038/mp.2013.110

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  45 in total

1.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

2.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

Review 3.  Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury.

Authors:  Dan Shlosberg; Mony Benifla; Daniela Kaufer; Alon Friedman
Journal:  Nat Rev Neurol       Date:  2010-06-15       Impact factor: 42.937

4.  NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice.

Authors:  Sika Zheng; Stephen M Eacker; Suk Jin Hong; Richard M Gronostajski; Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2010-07       Impact factor: 14.808

Review 5.  Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis.

Authors:  Klaus-Peter Wandinger; Sandra Saschenbrecker; Winfried Stoecker; Josep Dalmau
Journal:  J Neuroimmunol       Date:  2010-10-15       Impact factor: 3.478

6.  N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica.

Authors:  Russell C Dale; Sarosh R Irani; Fabienne Brilot; Sekhar Pillai; Richard Webster; Deepak Gill; Bethan Lang; Angela Vincent
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

Review 7.  Infections as triggers and complications of systemic lupus erythematosus.

Authors:  A Doria; M Canova; M Tonon; M Zen; E Rampudda; N Bassi; F Atzeni; S Zampieri; A Ghirardello
Journal:  Autoimmun Rev       Date:  2008-08-12       Impact factor: 9.754

8.  Effect of an NMDA receptor agonist on T-maze and passive avoidance test in 12-week streptozotocin-induced diabetic rats.

Authors:  Emilia Grzeda; Róza J Wiśniewska; Konstanty Wiśniewski
Journal:  Pharmacol Rep       Date:  2007 Nov-Dec       Impact factor: 3.024

Review 9.  Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?

Authors:  Frank R Sharp; Robert L Hendren
Journal:  Epilepsy Behav       Date:  2007-04-06       Impact factor: 2.937

10.  Disease-relevant autoantibodies in first episode schizophrenia.

Authors:  Michael S Zandi; Sarosh R Irani; Bethan Lang; Patrick Waters; Peter B Jones; Peter McKenna; Alasdair J Coles; Angela Vincent; Belinda R Lennox
Journal:  J Neurol       Date:  2010-10-26       Impact factor: 4.849

View more
  126 in total

Review 1.  Neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Jenny J Linnoila; Myrna R Rosenfeld; Josep Dalmau
Journal:  Semin Neurol       Date:  2014-11-04       Impact factor: 3.420

Review 2.  Psychosis: an autoimmune disease?

Authors:  Adam A J Al-Diwani; Thomas A Pollak; Sarosh R Irani; Belinda R Lennox
Journal:  Immunology       Date:  2017-08-03       Impact factor: 7.397

Review 3.  Antineuronal antibodies against neurotransmitter receptors and synaptic proteins in schizophrenia: current knowledge and clinical implications.

Authors:  Johann Steiner; Kolja Schiltz; Hans-Gert Bernstein; Bernhard Bogerts
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

4.  [Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment].

Authors:  Ludger Tebartz van Elst; Karl Bechter; Harald Prüss; Alkomiet Hasan; Jo Hann Steiner; Frank Leypoldt; Dominique Endres
Journal:  Nervenarzt       Date:  2019-07       Impact factor: 1.214

Review 5.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

Authors:  Josep Dalmau; Christian Geis; Francesc Graus
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 6.  Autoimmunity, Autoantibodies, and Autism Spectrum Disorder.

Authors:  Elizabeth Edmiston; Paul Ashwood; Judy Van de Water
Journal:  Biol Psychiatry       Date:  2016-09-01       Impact factor: 13.382

Review 7.  Autoimmune encephalopathies.

Authors:  Frank Leypoldt; Thaís Armangue; Josep Dalmau
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

8.  Chronic Toxoplasma gondii Infection Induces Anti-N-Methyl-d-Aspartate Receptor Autoantibodies and Associated Behavioral Changes and Neuropathology.

Authors:  Ye Li; Raphael P Viscidi; Geetha Kannan; Ross McFarland; Mikhail V Pletnikov; Emily G Severance; Robert H Yolken; Jianchun Xiao
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

9.  Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor.

Authors:  Makoto Hara; Eugenia Martinez-Hernandez; Helena Ariño; Thais Armangué; Marianna Spatola; Mar Petit-Pedrol; Albert Saiz; Myrna R Rosenfeld; Francesc Graus; Josep Dalmau
Journal:  Neurology       Date:  2018-03-16       Impact factor: 9.910

Review 10.  NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis?

Authors:  Joseph C Masdeu; Josep Dalmau; Karen F Berman
Journal:  Trends Neurosci       Date:  2016-04-26       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.